Ratings by Leerink (Daina Graybosch)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/7/2026 | BioNTech | BNTX | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/13/2026 | Century Therapeutics | IPSC | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/2/2026 | BioNTech | BNTX | Downgrade | Market Perform (Outperform) |
113.75 (90.62) |
-20.33% | Details | |
| 11/17/2025 | Century Therapeutics | IPSC | Downgrade | Market Perform (Outperform) |
0.47 (2.41) |
412.77% | Details | |
| 10/3/2025 | I-Mab | IMAB | New Coverage | Outperform (N/A) |
4.13 (4.63) |
12.11% | Details | |
| 9/18/2025 | Innate Pharma S.A. | IPHA | Downgrade | Market Perform (Outperform) |
2.08 (1.89) |
-9.13% | Details | |
| 9/3/2025 | Bolt Biotherapeutics, Inc. | BOLT | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/3/2025 | Fate Therapeutics | FATE | Maintain | Outperform (N/A) |
|
Details | ||
| 8/7/2025 | Compugen | CGEN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/6/2025 | Xilio Therapeutics Inc | XLO | New Coverage | Outperform (N/A) |
0.67 (8.90) |
1228.36% | Details | |
| 7/22/2025 | iTeos Therapeutics | ITOS | Maintain | Market Perform (N/A) |
|
Details | ||
| 6/11/2025 | Summit Therapeutics plc | SMMT | New Coverage | Underperform (N/A) |
22.08 (14.25) |
-35.46% | Details | |
| 5/14/2025 | iTeos Therapeutics | ITOS | Downgrade | Market Perform (Outperform) |
7.85 (10.15) |
29.3% | Details | |
| 4/17/2025 | BioNTech | BNTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/31/2025 | Lava Therapeutics NV | LVTX | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/11/2025 | 2Seventy Bio Inc. | TSVT | Downgrade | Market Perform (Outperform) |
2.80 (5.00) |
78.57% | Details | |
| 12/12/2024 | Lava Therapeutics NV | LVTX | Downgrade | Market Perform (Outperform) |
1.21 (1.74) |
43.8% | Details | |
| 11/13/2024 | BioNTech | BNTX | Maintain | Outperform (N/A) |
|
Details | ||
| 9/26/2024 | 2Seventy Bio Inc. | TSVT | Maintain | Outperform (N/A) |
|
Details | ||
| 5/15/2024 | Bolt Biotherapeutics, Inc. | BOLT | Downgrade | Market Perform (Outperform) |
1.33 (4.27) |
221.05% | Details | |
| 1/31/2024 | 2Seventy Bio Inc. | TSVT | Upgrade | Outperform (Market Perform) |
4.01 (5.00) |
24.69% | Details | |
| 10/30/2023 | 2Seventy Bio Inc. | TSVT | Downgrade | Market Perform (Outperform) |
2.15 (5.00) |
132.56% | Details | |
| 8/16/2023 | Turnstone Biologics | TSBX | New Coverage | Market Perform (N/A) |
11.73 (0.36) |
-96.93% | Details | |
| 5/12/2023 | Bolt Biotherapeutics, Inc. | BOLT | Upgrade | Outperform (Market Perform) |
1.60 (4.27) |
166.88% | Details | |
| 9/26/2022 | Lava Therapeutics NV | LVTX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/29/2022 | Molecular Partners | MOLN | Downgrade | Market Perform (Outperform) |
6.94 (3.81) |
-45.1% | Details | |
| 8/11/2022 | Bolt Biotherapeutics, Inc. | BOLT | Downgrade | Market Perform (Outperform) |
2.52 (4.27) |
69.44% | Details | |
| 6/23/2022 | F-Star Therapeutics Inc. | FSTX | Downgrade | Market Perform (Outperform) |
3.98 (7.12) |
78.89% | Details | |
| 4/21/2022 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 4/1/2022 | Silverback Therapeutics | SBTX | Downgrade | Market Perform (Outperform) |
3.51 (5.87) |
67.24% | Details | |
| 3/31/2022 | Arcellx Inc. | ACLX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/28/2022 | 2Seventy Bio Inc. | TSVT | Maintain | Outperform (N/A) |
|
Details | ||
| 3/1/2022 | Arcellx Inc. | ACLX | New Coverage | Outperform (N/A) |
19.14 (115.07) |
501.2% | Details | |
| 2/10/2022 | 2Seventy Bio Inc. | TSVT | New Coverage | Outperform (N/A) |
16.27 (5.00) |
-69.27% | Details | |
| 12/9/2021 | BioNTech | BNTX | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/12/2021 | Silverback Therapeutics | SBTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/12/2021 | iTeos Therapeutics | ITOS | Maintain | Outperform (N/A) |
|
Details | ||
| 10/5/2021 | BioNTech | BNTX | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/3/2021 | Innate Pharma S.A. | IPHA | Upgrade | Outperform (Market Perform) |
3.62 (2.08) |
-42.54% | Details | |
| 7/12/2021 | Molecular Partners | MOLN | New Coverage | Outperform (N/A) |
19.07 (3.81) |
-80.02% | Details | |
| 7/8/2021 | F-Star Therapeutics Inc. | FSTX | New Coverage | Outperform (N/A) |
7.34 (7.12) |
-3% | Details | |
| 4/30/2021 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 4/19/2021 | Lava Therapeutics NV | LVTX | New Coverage | Outperform (N/A) |
15.00 (1.74) |
-88.4% | Details | |
| 3/2/2021 | Bolt Biotherapeutics, Inc. | BOLT | New Coverage | Outperform (N/A) |
30.00 (4.27) |
-85.77% | Details | |
| 2/4/2021 | BioNTech | BNTX | Maintain | Market Perform (N/A) |
|
Details | ||
| 12/15/2020 | Innate Pharma S.A. | IPHA | Downgrade | Market Perform (Outperform) |
4.39 (3.62) |
-17.54% | Details | |
| 8/18/2020 | iTeos Therapeutics | ITOS | New Coverage | Outperform (N/A) |
32.92 (10.15) |
-69.17% | Details | |
| 8/11/2020 | Fate Therapeutics | FATE | Maintain | Outperform (N/A) |
|
Details | ||
| 8/7/2020 | BioNTech | BNTX | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/7/2020 | Compugen | CGEN | New Coverage | Outperform (N/A) |
13.22 (2.02) |
-84.72% | Details | |
| 4/29/2020 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 4/24/2020 | BioNTech | BNTX | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/30/2020 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 3/12/2020 | Fate Therapeutics | FATE | Maintain | Outperform (N/A) |
|
Details | ||
| 2/6/2020 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 1/31/2020 | Aduro Biotech | ADRO | Maintain | Outperform (N/A) |
|
Details | ||
| 1/24/2020 | BioNTech | BNTX | Downgrade | Market Perform (Outperform) |
36.70 (113.75) |
209.95% | Details | |
| 12/11/2019 | Synothorx Inc. | THOR | Downgrade | Market Perform (Outperform) |
67.71 (24.98) |
-63.11% | Details | |
| 11/15/2019 | Genocea Biosciences | GNCA | New Coverage | Outperform (N/A) |
2.24 (0.05) |
-97.77% | Details | |
| 11/6/2019 | Fate Therapeutics | FATE | Maintain | Outperform (N/A) |
|
Details | ||
| 11/4/2019 | BioNTech | BNTX | New Coverage | Outperform (N/A) |
16.52 (36.70) |
122.15% | Details | |
| 9/13/2019 | Tocagen Inc. | TOCA | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/22/2019 | Tocagen Inc. | TOCA | Maintain | Market Perform (N/A) |
|
Details |
